Welcome
Support Centre
22 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Randomised controlled trial for the treatment of hand arthrosis with prednisolone and naproxen
ISRCTN ISRCTN68990076
ClinicalTrials.gov identifier
Public title Randomised controlled trial for the treatment of hand arthrosis with prednisolone and naproxen
Scientific title
Acronym BELIOA2
Serial number at source IDS 04-05
Study hypothesis The primary hypothesis is that patients with hand arthrosis treated with prednisolone for one week (3 days 50 mg, 4 days 25 mg) will improve significantly in different clinical parameters
Lay summary
Ethics approval The study was approved by the Internal Review Board and Ethical Committee of the Vienna Medical University on 14/02/2006, reference number 481/2005
Study design Single-centre, randomised, double-blind, placebo-controlled clinical trial
Countries of recruitment Austria
Disease/condition/study domain Hand arthrosis
Participants - inclusion criteria 1. Hand arthrosis
2. Age over 18 years
3. Pain on a 100 mm Visual Analogue Scale (VAS) in the target hand more than 40 mm
4. Willingness to comply with the protocol
Participants - exclusion criteria 1. Current treatment with steroids
2. Cardiac insufficiency
3. Infection
4. Uncontrolled hypertension
5. History of gastrointestinal bleeding
6. Diabetes mellitus
7. Allergy against study medication
8. Pregnancy
Anticipated start date 01/12/2005
Anticipated end date 01/12/2006
Status of trial Completed
Patient information material
Target number of participants 246
Interventions Patients are randomised to receive treatment with either prednisolone or naproxen or placebo
Primary outcome measure(s) Pain in the target hand measured on a 100 mm VAS
Secondary outcome measure(s) 1. Morning stiffness
2. VAS for disease activity
3. Tender and swollen joint counts (inflammatory and bony swelling)
4. Functioning measured with:
a. Health Assessment Questionnaire (HAQ)
b. Score for Assessment and Quantification of Chronic Rheumatic Affections of the Hands (SACRAH)
c. Arthritis Impact Measurement Scales 2 - Short Form (AIMS2-SF)
d. Grip strength
e. Moberg picking-up test
Sources of funding Vienna Medical University (Austria)
Trial website
Publications
Contact name Prof  Josef  Smolen
  Address Department of Internal Medicine III
Division of Rheumatology
Wahringer Gurtel 18-20
  City/town Vienna
  Zip/Postcode A-1090
  Country Austria
  Tel +43 (0)140 400 4381
  Email josef.smolen@wienkav.at
Sponsor Vienna Medical University (Austria)
  Address Department of Internal Medicine III
Division of Rheumatology
Wahringer Gurtel 18-20
  City/town Vienna
  Zip/Postcode A-1090
  Country Austria
Date applied 23/11/2005
Last edited 13/03/2006
Date ISRCTN assigned 10/03/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central